FDA Grants Accelerated Approval to Vera Therapeutics’ Trutakna for IgA Nephropathy, First Dual BAFF–APRIL Therapy

WASHINGTON — The U.S. Food and Drug Administration (FDA) on July 7, 2026, granted accelerated approval to Trutakna (atacicept), a self-administered injectable from Vera Therapeutics for adults with primary immunoglobulin A (IgA) nephropathy. This chronic and potentially life-threatening kidney disorder, also known as Berger’s disease, often leads to progressive renal failure. The regulatory milestone introduces a first-in-class biochemical approach to a rapidly evolving medical landscape, providing patients with an at-home treatment option that blocks two distinct immune system pathways simultaneously. The FDA’s decision was based on a late-stage clinical trial showing a substantial, rapid reduction of protein in the urine, a critical marker used by clinicians to assess active kidney damage.

A New Biological Mechanism: Dual-Target Inhibition

Trutakna represents a notable therapeutic shift as the first approved drug for IgA nephropathy that targets both B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL). These two signaling proteins, or cytokines, drive the survival and maturation of specific immune cells that produce abnormal antibodies.

In patients with IgA nephropathy, the body generates a mutated, “galactose-deficient” form of IgA antibodies. The immune system flags these abnormal molecules, forming large molecular clusters called immune complexes. As blood filters through the kidneys, these complexes become physically trapped in the glomeruli—the microscopic filtering units of the organ. The resulting entrapment causes persistent inflammation, tissue scarring, and leakiness, which manifests clinically as proteinuria (excess protein in the urine).

By blocking both BAFF and APRIL upstream, Trutakna curtails the biological signals necessary for these harmful antibodies to form. This dual action aims to stop the inflammatory cascade before the filters suffer irreversible structural damage.

Strong Trial Results: Slashing Proteinuria

The FDA’s accelerated approval was heavily supported by data from the prespecified 36-week interim analysis of ORIGIN 3, an ongoing global, multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. The study enrolled 431 adults with biopsy-confirmed IgA nephropathy who were already receiving optimal supportive care, such as blood pressure-regulating medications.

ORIGIN 3 Phase 3 Trial Interim Results (Week 36)
┌────────────────────────────────────────────────────────┐
│  Trutakna 150mg Weekly (n=106) vs. Placebo (n=97)      │
├────────────────────────────────────────────────────────┤
│  Proteinuria Reduction From Baseline:                  │
│  ■■■■■■■■■■■■■■■■■■■■■■■■■■■■■■ 46% (Trutakna)         │
│  ■■ 6.8% (Placebo)                                    │
├────────────────────────────────────────────────────────┤
│  Placebo-Adjusted Relative Reduction: 42% (p < 0.0001) │
└────────────────────────────────────────────────────────┘

The primary efficacy endpoint focused on the 24-hour urine protein-to-creatinine ratio (UPCR) in the first 203 randomized participants. The findings revealed:

• 46% absolute reduction in proteinuria from baseline levels among patients receiving a once-weekly 150 mg subcutaneous injection of Trutakna.

• 42% greater relative reduction in urine protein compared to the placebo group at the 36-week mark, a result that was highly statistically significant ($P < 0.0001$).

• 68% reduction in the circulating pathogenic antibody (galactose-deficient IgA1) compared to the placebo cohort, validating the drug’s upstream mechanism of action.

Expert Perspectives on the Evolving Care Landscape

Nephrologists not involved in the design of the trial view the substantial reductions in proteinuria as a positive clinical indicator, though they emphasize the need for long-term confirmation.

“An agent that reduces proteinuria substantially could change the long-term disease trajectory for many patients,” noted an independent nephrologist commenting on the approval. “Historically, lower proteinuria is strongly associated with a slower progression toward end-stage renal disease and a reduced need for dialysis or organ transplantation.”

However, medical experts maintain a balanced caution regarding the regulatory pathway utilized. The FDA’s accelerated approval program allows for the early marketing of drugs targeting serious conditions based on a surrogate endpoint—a laboratory measurement like protein reduction that is reasonably likely to predict a real clinical benefit.

Independent experts emphasize that this pathway requires definitive confirmatory evidence showing that the drug preserves actual kidney function over an extended period. To address this requirement, the ORIGIN 3 trial remains blinded and ongoing. Researchers are actively tracking the participants’ estimated glomerular filtration rate (eGFR), which measures how efficiently the kidneys filter waste from the blood. Following a revised analysis plan aligned with the FDA in June 2026, these pivotal eGFR data have been pulled forward, with initial confirmatory results anticipated in the third quarter of 2026.

Shifting Paradigms in Public Health and Patient Access

For decades, the standard of care for IgA nephropathy was restricted to non-specific management, including strict blood pressure control with ACE inhibitors or ARBs, and broad, systemic immunosuppressed regimens like high-dose corticosteroids, which often carry severe systemic side effects. Up to 30% of affected individuals progressed to total kidney failure within 20 years of diagnosis.

Trutakna joins a rapidly expanding group of targeted medications. Over the last few years, the market has seen the introduction of specialized therapies with differing mechanisms, including targeted corticosteroids (Tarpeyo), dual endothelin-angiotensin receptor antagonists (Filspari), complement inhibitors (Fabhalta), and single-target anti-APRIL monoclonal antibodies (Voyxact).

For public health, Trutakna’s primary advantage rests on its delivery system. Packaged as a prefilled autoinjector for at-home use, it offers a disease-modifying biologic that does not require regular outpatient clinic visits for intravenous or healthcare-administered infusions, potentially expanding access for individuals living far from specialized medical centers.

Safety Concerns, Uncertainties, and Financial Hurdles

As an immunomodulatory therapy, Trutakna carries specific safety risks linked to its mechanism. Because it dampens pathways governing B-cell survival, it inherently suppresses portions of the patient’s immune system, which can increase vulnerability to pathogens.

In the safety cohort of 428 patients from the ORIGIN 3 trial, adverse events occurred in 59.3% of the Trutakna group compared to 50.0% of the placebo group. The vast majority of these reactions were mild-to-moderate and resolved without stopping therapy.

• Infections: Reported in 32% of treated patients versus 28% on placebo, with upper respiratory tract infections being the most frequent (12% vs. 9%).

• Injection Site Reactions: Localized administration effects, such as redness (erythema) or swelling, were noted in 30% of the treatment group compared to 5% of the placebo group.

Importantly, no serious, severe, or opportunistic infections were observed during the 36-week interim evaluation. The FDA advises clinicians to thoroughly screen patients for active infections before starting treatment and to avoid administering live vaccines within 30 days of initiating or during therapy.

Beyond clinical risks, economic barriers present a challenge to widespread integration. Vera Therapeutics announced a commercial list price of approximately $425,000 per year for Trutakna. This pricing is slightly higher than the estimated $390,000 annualized cost of its closest direct single-target competitor, Voyxact. Insurance companies, institutional payers, and clinical networks will need to evaluate these high list prices against long-term cost-offsets, such as preventing the massive lifetime healthcare expenses associated with chronic dialysis and renal transplantation.

Guidance for Patients and Consumers

The introduction of Trutakna alters the choices available for kidney care, but it requires careful navigation by patients and healthcare providers.

• Maintain Existing Regimens: Patients diagnosed with primary IgA nephropathy must not alter, reduce, or discontinue their current therapeutic plans or blood pressure medications without direct consultation with their treating nephrologist.

• Routine Diagnostic Monitoring: Individuals living with chronic kidney disease or persistent protein indicators should maintain regular diagnostic schedules. Tracking 24-hour urine protein levels, checking blood pressure daily, and monitoring routine eGFR blood tests remain fundamental to tracking kidney health.

• Engage Care Teams: Patients should discuss these newly emerging targeted options with their nephrology teams to evaluate whether a dual BAFF-APRIL inhibitor aligns with their specific clinical profile, disease progression rate, and insurance coverage.

Reference Section

• • Reuters. “US FDA approves Vera’s kidney disease drug.” July 7, 2026.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.